We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A picture of Laura Elizabeth Lansdowne

Laura Elizabeth Lansdowne profile page

Managing Editor

 at Technology Networks


As managing editor, Laura works with the editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She oversees the in-house editorial team and works directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial-based roles, before joining Technology Networks in 2017.


Education


University of Kent  

Nottingham Trent University  

Writtle University College  

Chartered Institute of Editing and Proofreading  


Accreditations


Biology, BSc (Hons) recognised by The University of Kent


Areas of Expertise



Got a Question for Laura Elizabeth Lansdowne?


Get in touch using the contact form linked here and we’ll get back to you shortly



Published Content
Total: 409
What is a Biopharmaceutical? content piece image
Infographic

What is a Biopharmaceutical?

This infographic is designed to provide an overview of the different types of biopharmaceuticals, with a specific emphasis on monoclonal antibodies.
Challenges in ELN Adoption content piece image
Infographic

Challenges in ELN Adoption

This infographic aims to summarize the advantages and challenges associated with adopting Electronic Laboratory Notebooks (ELNs).
Article

Researchers Discover a Promising Drug Target for Bowel Cancer

The identification of this target is particularly exciting as it is unique to tumour cells, meaning that it is less toxic compared to existing therapies.
Exploring the Drug Discovery and Development Pipeline content piece image
Infographic

Exploring the Drug Discovery and Development Pipeline

Drug discovery and development can take up to 15 years and cost over $1 billion dollars. This infographic details the steps involved from conceptualization of a treatment to bringing it to market.
Article

Umbilical Cord-Derived Stem Cells Could Help Those with Heart Failure

Umbilical cord-derived stem cells could be the answer for patients with heart failure. A study published yesterday, indicates that cardiac muscle function and quality-of-life could be enhanced after treatment with this specific type of stem cell.
Article

Encouraging Step Towards a Potential Therapeutic Strategy for Asthma

Researchers have discovered a compound with the ability to induce long-lasting bronchorelaxation and prevent hyperreactivity in murine models of asthma.
Article

Could a Lipid be the Key to Treating Chronic Inflammatory Diseases?

The lipid, 10-nitro-oleic-acid, an endogenous nitro-fatty acid (NFA) modulator, is being explored as a treatment for chronic inflammatory diseases. Prof. Valerie O'Donnell's group was one of the few that originally identified the lipid’s ability to reduce inflammation.
Article

LipidFinder: An Open-Source Python Workflow for Novel Lipid Discovery

Researchers at the University of Cardiff, UK have developed a Python based computational workflow that is tailored to the analysis of large volumes of data, with the ability to identify novel lipids.
Industry Insight

Cell-based Imaging and Screening Applications

BioStatus develops and supplies products for cell-based imaging, cytometry and screening applications. We met with Roy Edward, Director at BioStatus during the High Content and Phenotypic Screening 2017 event to learn more.
Advertisement